RET Fusion Testing in Patients With NSCLC: The RETING Study
Introduction: RET inhibitors with impressive overall response rates are now available for patients with NSCLC, yet the identi fication of RET fusions remains a dif ficult challenge. Most guidelines encourage the upfront use of next -generation sequencing (NGS), or alternatively, fluorescence in situ...
| Autores: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2024 |
| País: | España |
| Institución: | Universidad de Barcelona |
| Repositorio: | Dipòsit Digital de la UB |
| OAI Identifier: | oai:diposit.ub.edu:2445/214201 |
| Acceso en línea: | https://hdl.handle.net/2445/214201 |
| Access Level: | acceso abierto |
| Palabra clave: | Càncer de pulmó Creatina quinasa Lung cancer Creatine kinase |
| id |
ES_03d6944d642db8f2fb01ebc7f40bb2a1 |
|---|---|
| oai_identifier_str |
oai:diposit.ub.edu:2445/214201 |
| network_acronym_str |
ES |
| network_name_str |
España |
| repository_id_str |
|
| spelling |
RET Fusion Testing in Patients With NSCLC: The RETING StudyConde, EstherHernández, SusanaRodríguez Carrillo, Jose LuisMartínez, RebecaAlonso, MartaCurto, DanielJiménez, BeatrizCaminoa, AlejandraBenito, AmparoGarrido, PilarClave, SergiArriola, EdurneEsteban Rodríguez, IsabelCastro, Javier deSansano, IreneFelip, EnriquetaRojo, FedericoDómine, ManuelAbdulkader, IhabGarcía González, JorgeTeixidó Febrero, CristinaReguart, NoemíCompañ, DesamparadosInsa, AmeliaMancheño, NuriaPalanca, SaraiJuan Vidal, OscarBaixeras, NuriaNadal, ErnestCebollero, MariaCalles Blanco, AntonioMartín, PalomaSalas, ClaraProvencio, MarianoAranda, IgnacioMassuti, BartomeuLópez Vilaro, LauraMajem, MargaritaPaz-Ares, LuisLópez Rios, FernandoCàncer de pulmóCreatina quinasaLung cancerCreatine kinaseIntroduction: RET inhibitors with impressive overall response rates are now available for patients with NSCLC, yet the identi fication of RET fusions remains a dif ficult challenge. Most guidelines encourage the upfront use of next -generation sequencing (NGS), or alternatively, fluorescence in situ hybridization (FISH) or reverse transcriptase-polymerase chain reaction (RT-PCR) when NGS is not possible or available. Taken together, the suboptimal performance of single-analyte assays to detect RET fusions, although consistent with the notion of encouraging universal NGS, is currently widening some of the clinical practice gaps in the implementation of predictive biomarkers in patients with advanced NSCLC. Methods: This situation prompted us to evaluate several RET assays in a large multicenter cohort of RET fusion -positive NSCLC (n 1 / 4 38) to obtain real -world data. In addition to RNA -based NGS (the criterion standard method), all positive specimens underwent break -apart RET FISH with two different assays and were also tested by an RT-PCR assay. Results: The most common RET partners were KIF5B (78.9%), followed by CCDC6 (15.8%). The two RET NGSpositive but FISH -negative samples contained a KIF5B(15)RET(12) fusion. The three RET fusions not identi fied with RT-PCR were AKAP13(35)-RET(12) , KIF5B(24)-RET(9) and KIF5B(24)-RET(11) . All three false -negative RT-PCR cases were FISH -positive, exhibited a typical break -apart pattern, and contained a very high number of positive tumor cells with both FISH assays. Signet ring cells, psammoma bodies, and pleomorphic features were frequently observed (in 34.2%, 39.5%, and 39.5% of tumors, respectively). Conclusions: In-depth knowledge of the advantages and disadvantages of the different RET testing methodologies could help clinical and molecular tumor boards implement and maintain sensible algorithms for the rapid and effective detection of RET fusions in patients with NSCLC. The likelihood of RET false -negative results with both FISH and RT-PCR reinforces the need for upfront NGS in patients with NSCLC. (c) 2024 The Authors. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Elsevier BV2024info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/2445/214201Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))reponame:Dipòsit Digital de la UBinstname:Universidad de BarcelonaInglésReproducció del document publicat a: https://doi.org/10.1016/j.jtocrr.2024.100653JTO Clinical and Research Reports, 2024, vol. 5, num. 4https://doi.org/10.1016/j.jtocrr.2024.100653cc by (c) Conde, Esther et al, 2024http://creativecommons.org/licenses/by/3.0/es/info:eu-repo/semantics/openAccessoai:diposit.ub.edu:2445/2142012026-05-27T06:46:51Z |
| dc.title.none.fl_str_mv |
RET Fusion Testing in Patients With NSCLC: The RETING Study |
| title |
RET Fusion Testing in Patients With NSCLC: The RETING Study |
| spellingShingle |
RET Fusion Testing in Patients With NSCLC: The RETING Study Conde, Esther Càncer de pulmó Creatina quinasa Lung cancer Creatine kinase |
| title_short |
RET Fusion Testing in Patients With NSCLC: The RETING Study |
| title_full |
RET Fusion Testing in Patients With NSCLC: The RETING Study |
| title_fullStr |
RET Fusion Testing in Patients With NSCLC: The RETING Study |
| title_full_unstemmed |
RET Fusion Testing in Patients With NSCLC: The RETING Study |
| title_sort |
RET Fusion Testing in Patients With NSCLC: The RETING Study |
| dc.creator.none.fl_str_mv |
Conde, Esther Hernández, Susana Rodríguez Carrillo, Jose Luis Martínez, Rebeca Alonso, Marta Curto, Daniel Jiménez, Beatriz Caminoa, Alejandra Benito, Amparo Garrido, Pilar Clave, Sergi Arriola, Edurne Esteban Rodríguez, Isabel Castro, Javier de Sansano, Irene Felip, Enriqueta Rojo, Federico Dómine, Manuel Abdulkader, Ihab García González, Jorge Teixidó Febrero, Cristina Reguart, Noemí Compañ, Desamparados Insa, Amelia Mancheño, Nuria Palanca, Sarai Juan Vidal, Oscar Baixeras, Nuria Nadal, Ernest Cebollero, Maria Calles Blanco, Antonio Martín, Paloma Salas, Clara Provencio, Mariano Aranda, Ignacio Massuti, Bartomeu López Vilaro, Laura Majem, Margarita Paz-Ares, Luis López Rios, Fernando |
| author |
Conde, Esther |
| author_facet |
Conde, Esther Hernández, Susana Rodríguez Carrillo, Jose Luis Martínez, Rebeca Alonso, Marta Curto, Daniel Jiménez, Beatriz Caminoa, Alejandra Benito, Amparo Garrido, Pilar Clave, Sergi Arriola, Edurne Esteban Rodríguez, Isabel Castro, Javier de Sansano, Irene Felip, Enriqueta Rojo, Federico Dómine, Manuel Abdulkader, Ihab García González, Jorge Teixidó Febrero, Cristina Reguart, Noemí Compañ, Desamparados Insa, Amelia Mancheño, Nuria Palanca, Sarai Juan Vidal, Oscar Baixeras, Nuria Nadal, Ernest Cebollero, Maria Calles Blanco, Antonio Martín, Paloma Salas, Clara Provencio, Mariano Aranda, Ignacio Massuti, Bartomeu López Vilaro, Laura Majem, Margarita Paz-Ares, Luis López Rios, Fernando |
| author_role |
author |
| author2 |
Hernández, Susana Rodríguez Carrillo, Jose Luis Martínez, Rebeca Alonso, Marta Curto, Daniel Jiménez, Beatriz Caminoa, Alejandra Benito, Amparo Garrido, Pilar Clave, Sergi Arriola, Edurne Esteban Rodríguez, Isabel Castro, Javier de Sansano, Irene Felip, Enriqueta Rojo, Federico Dómine, Manuel Abdulkader, Ihab García González, Jorge Teixidó Febrero, Cristina Reguart, Noemí Compañ, Desamparados Insa, Amelia Mancheño, Nuria Palanca, Sarai Juan Vidal, Oscar Baixeras, Nuria Nadal, Ernest Cebollero, Maria Calles Blanco, Antonio Martín, Paloma Salas, Clara Provencio, Mariano Aranda, Ignacio Massuti, Bartomeu López Vilaro, Laura Majem, Margarita Paz-Ares, Luis López Rios, Fernando |
| author2_role |
author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author |
| dc.subject.none.fl_str_mv |
Càncer de pulmó Creatina quinasa Lung cancer Creatine kinase |
| topic |
Càncer de pulmó Creatina quinasa Lung cancer Creatine kinase |
| description |
Introduction: RET inhibitors with impressive overall response rates are now available for patients with NSCLC, yet the identi fication of RET fusions remains a dif ficult challenge. Most guidelines encourage the upfront use of next -generation sequencing (NGS), or alternatively, fluorescence in situ hybridization (FISH) or reverse transcriptase-polymerase chain reaction (RT-PCR) when NGS is not possible or available. Taken together, the suboptimal performance of single-analyte assays to detect RET fusions, although consistent with the notion of encouraging universal NGS, is currently widening some of the clinical practice gaps in the implementation of predictive biomarkers in patients with advanced NSCLC. Methods: This situation prompted us to evaluate several RET assays in a large multicenter cohort of RET fusion -positive NSCLC (n 1 / 4 38) to obtain real -world data. In addition to RNA -based NGS (the criterion standard method), all positive specimens underwent break -apart RET FISH with two different assays and were also tested by an RT-PCR assay. Results: The most common RET partners were KIF5B (78.9%), followed by CCDC6 (15.8%). The two RET NGSpositive but FISH -negative samples contained a KIF5B(15)RET(12) fusion. The three RET fusions not identi fied with RT-PCR were AKAP13(35)-RET(12) , KIF5B(24)-RET(9) and KIF5B(24)-RET(11) . All three false -negative RT-PCR cases were FISH -positive, exhibited a typical break -apart pattern, and contained a very high number of positive tumor cells with both FISH assays. Signet ring cells, psammoma bodies, and pleomorphic features were frequently observed (in 34.2%, 39.5%, and 39.5% of tumors, respectively). Conclusions: In-depth knowledge of the advantages and disadvantages of the different RET testing methodologies could help clinical and molecular tumor boards implement and maintain sensible algorithms for the rapid and effective detection of RET fusions in patients with NSCLC. The likelihood of RET false -negative results with both FISH and RT-PCR reinforces the need for upfront NGS in patients with NSCLC. (c) 2024 The Authors. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
| publishDate |
2024 |
| dc.date.none.fl_str_mv |
2024 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.none.fl_str_mv |
https://hdl.handle.net/2445/214201 |
| url |
https://hdl.handle.net/2445/214201 |
| dc.language.none.fl_str_mv |
Inglés |
| language_invalid_str_mv |
Inglés |
| dc.relation.none.fl_str_mv |
Reproducció del document publicat a: https://doi.org/10.1016/j.jtocrr.2024.100653 JTO Clinical and Research Reports, 2024, vol. 5, num. 4 https://doi.org/10.1016/j.jtocrr.2024.100653 |
| dc.rights.none.fl_str_mv |
cc by (c) Conde, Esther et al, 2024 http://creativecommons.org/licenses/by/3.0/es/ info:eu-repo/semantics/openAccess |
| rights_invalid_str_mv |
cc by (c) Conde, Esther et al, 2024 http://creativecommons.org/licenses/by/3.0/es/ |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.publisher.none.fl_str_mv |
Elsevier BV |
| publisher.none.fl_str_mv |
Elsevier BV |
| dc.source.none.fl_str_mv |
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) reponame:Dipòsit Digital de la UB instname:Universidad de Barcelona |
| instname_str |
Universidad de Barcelona |
| reponame_str |
Dipòsit Digital de la UB |
| collection |
Dipòsit Digital de la UB |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1869402753768357888 |
| score |
15,812429 |